Refine by
Early Disease Detection Articles & Analysis: Older
46 news found
From data to diagnostics and imaging, drug development and discovery, early intervention and predictive analytics, remote patient monitoring and robotics, AI is revolutionizing healthcare as we know it. ...
The service provides a comprehensive overview of all viral genetic material present in a sample, enabling the detection of both known and previously unknown viruses in a single assay. ...
” Lifespin is working to build new precision medicine tools based on quantitative metabolic profiles and proprietary algorithms to assist in the early detection of diseases and monitoring the efficacy of health treatments. To facilitate these services, the company has established one of the largest and most comprehensive databases of ...
Koios Medical, Inc has received 510(k) clearance from the U.S. Food and Drug Administration for Koios DS (Decision Support) Breast 2.0, a new version of its machine learning based platform that assists physicians in the classification and diagnosis of breast cancer. The software offers a proprietary alignment to BI-RADS® for any lesion analyzed and is available connected to PACS and/or ...
Villines is board-certified in internal medicine, cardiovascular diseases, cardiac computed tomography, and advanced adult echocardiography. ...
ByElucid
Proprietary microRNA signature (miRisk) may support immunotherapy treatment decisions as a blood-based complementary diagnostic Results published in Journal of Thoracic Oncology Clinical and Research Reports Hummingbird Diagnostics GmbH, a leader in reading blood-based microRNAs for early disease detection and characterization, today ...
Hummingbird Diagnostics GmbH, a leader in reading blood-based microRNAs for early disease detection and characterization, today announced the publication of a study in the journal npj Precision Oncology that describes the discovery and validation of miRisk, a first-of-its-kind microRNA (miRNA) biomarker signature that offers the prospect of a ...
(OTCQB: GTHP) is the maker of a rapid and painless testing platform based on its patented biophotonic technology that utilizes light for the early detection of disease at the cellular level. The Company’s first product is the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical ...
Featured at this year’s event, Kevin Harris, President and co-Founder of CureMetrix, will present new and national research on breast cancer detection and will show how leveraging AI to stratify the risk of Coronary Heart Disease (CHD) by detecting and quantifying Breast Arterial Calcifications (BAC) can benefit imaging centers, healthcare ...
He has been instrumental in launching and scaling many industry-first technologies including the first Computer Aided Detection algorithm for the early detection of breast cancer, the first mammography analytics platform and a multi-point risk stratified breast screening scorecard. ...
n response to President Biden’s relaunch of Cancer Moonshot and his White House commitment to end cancer as we know it, healthcare technology executives for CureMetrix and CureMatch highlighted joint innovation as core to better detection and more personalized cancer treatment. “We commend President Biden’s program to end cancer as we know it, which starts with early detection ...
The KBCT is expected to optimize early disease detection, diagnosis, intervention, and treatment, and will improve survival rates for millions of patients worldwide. ...
(OTCQB: GTHP) is the maker of a rapid and painless testing platform based on its patented biophotonic technology that utilizes light for the early detection of disease at the cellular level. The Company’s first product is the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical ...
The KBCT is expected to optimize early disease detection, diagnosis, intervention and treatment, and will improve survival rates for millions of patients worldwide. ...
The KBCT is expected to optimize early disease detection, diagnosis, intervention and treatment, and will improve survival rates for millions of patients worldwide. ...
Riverain developed the first concurrent read FDA cleared algorithm for the early and efficient detection of lung disease. Riverain’s clinically trusted and proven solutions, ClearRead™ CT and ClearRead Xray, remove vessel and bone structure noise, proven to increase efficiency across all chest studies, while simultaneously increasing ...
ByAidoc
(OTCQB: GTHP) is the maker of a rapid and painless testing platform based on its patented biophotonic technology that utilizes light for the early detection of disease at the cellular level. The Company’s first product is the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical ...
The KBCT is expected to optimize early disease detection, diagnosis, intervention and treatment, and will improve survival rates for millions of patients worldwide. ...
The focus is not only on female-only health challenges, but female-prevalent diseases and those conditions that affect or present differently in women. ...
(OTCQB: GTHP) is the maker of a rapid and painless testing platform based on its patented biophotonic technology that utilizes light for the early detection of disease at the cellular level. The Company’s first product is the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical ...